Skip to main content
oralstrong evidence

Oral Mucositis Prevention

Published: Last updated:

Source: MASCC/ISOO Guidelines

Protocol for preventing and treating oral mucositis in cancer patients undergoing chemotherapy or radiation therapy. This is one of the strongest evidence-based applications of PBM, endorsed by the Multinational Association of Supportive Care in Cancer (MASCC).

Protocol Parameters

ConditionOral Mucositis (Chemotherapy/Radiation)
Wavelengths630nm, 660nm
Dosage2-3 J/cm² per point
Irradiance20-50 mW/cm²
Duration30-60 seconds per point
FrequencyDaily during chemo/radiation course
Body Zoneoral cavity
Evidence LevelStrong

Mechanism of Action

PBM promotes mucosal epithelial cell survival and regeneration, reduces local inflammatory response, and enhances wound healing in the oral mucosa. It reduces both the incidence and severity of mucositis, decreasing pain, improving oral intake, and potentially reducing hospital stays.

Key Studies

  • Bensadoun et al. (2006) - PBM for oral mucositis prevention
  • Bjordal et al. (2011) - Systematic review confirming efficacy
  • Zadik et al. (2019) - MASCC/ISOO guidelines update

Treatment Tips

  • *Must be initiated BEFORE mucositis develops (preventive use)
  • *Treat the entire oral mucosa, not just affected areas
  • *Daily treatment throughout the cancer therapy course
  • *This is a clinical application - coordinate with oncology team

Contraindications

  • !Direct irradiation of the tumor site is controversial
  • !Must be coordinated with oncology team

Research Basis

This content is informed by 47+ published peer-reviewed studies on photobiomodulation.